Table 6.
Relative risks, attributable fractions in the exposed and population-attributable risks for high- vs. low-tobacco-exposure nations, respectively.
| Cancer | p-Value | RR (C.I.) | AFE (C.I.) | PAF (C.I.) |
|---|---|---|---|---|
| Oropharynx | 0.0000 | 3.627 (3.6028, 3.6514) | 0.7243 (0.7224, 0.7261) | 0.5043 (0.5019, 0.5066) |
| Cervix | 0.0000 | 1.9962 (1.9932, 1.9992) | 0.499 (0.4983, 0.4998) | 0.2763 (0.2757, 0.2769) |
| Stomach | 0.0000 | 1.8241 (1.8216, 1.8266) | 0.4518 (0.451, 0.4525) | 0.2468 (0.2463, 0.2474) |
| Kidney | 0.0000 | 1.7574 (1.7549, 1.7599) | 0.431 (0.4302, 0.4318) | 0.2315 (0.2309, 0.2321) |
| Prostate | 0.0000 | 1.6336 (1.6328, 1.6344) | 0.3879 (0.3876, 0.3882) | 0.1964 (0.1962, 0.1966) |
| Pancreas | 0.0000 | 1.601 (1.5985, 1.6035) | 0.3754 (0.3744, 0.3764) | 0.1929 (0.1923, 0.1935) |
| Corpus Uteri | 0.0000 | 1.5789 (1.577, 1.5808) | 0.3666 (0.3659, 0.3674) | 0.1758 (0.1753, 0.1763) |
| Leukaemia | 0.0000 | 1.5676 (1.565, 1.5701) | 0.3621 (0.361, 0.3631) | 0.1615 (0.1609, 0.1621) |
| All Cancers | 0.0000 | 1.5195 (1.5186, 1.5203) | 0.3419 (0.3415, 0.3423) | 0.2234 (0.2231, 0.2237) |
| Ovary | 0.0000 | 1.4957 (1.4936, 1.4978) | 0.3314 (0.3305, 0.3323) | 0.1596 (0.1591, 0.1602) |
| Larynx | 0.0000 | 1.453 (1.4495, 1.4565) | 0.3118 (0.3101, 0.3134) | 0.1549 (0.1539, 0.1559) |
| Lung | 0.0000 | 1.442 (1.4409, 1.4431) | 0.3065 (0.306, 0.3071) | 0.1479 (0.1476, 0.1482) |
| Oesophagus | 0.0000 | 1.3267 (1.3236, 1.3298) | 0.2462 (0.2445, 0.248) | 0.115 (0.114, 0.1159) |
| All Cancers nNMSC | 0.0000 | 1.3089 (1.3086, 1.3093) | 0.236 (0.2358, 0.2362) | 0.0995 (0.0994, 0.0996) |
| Oropharynx_Broad | 0.0000 | 1.2962 (1.2905, 1.302) | 0.2285 (0.2251, 0.232) | 0.1432 (0.1408, 0.1456) |
| Brain | 0.0000 | 1.0472 (1.0452, 1.0492) | 0.0451 (0.0432, 0.0469) | 0.0178 (0.017, 0.0185) |
| Colorectum | 0.0000 | 1.0408 (1.0402, 1.0415) | 0.0392 (0.0386, 0.0398) | 0.0155 (0.0152, 0.0157) |
| Breast | 0.0000 | 1.0281 (1.0275, 1.0286) | 0.0273 (0.0268, 0.0278) | 0.011 (0.0107, 0.0112) |
| Liver | 2.25 × 10−34 | 1.0122 (1.0102, 1.0141) | 0.012 (0.0101, 0.0139) | 0.0049 (0.0041, 0.0056) |
| Bladder | 5.05 × 10−45 | 1.0089 (1.0076, 1.0101) | 0.0088 (0.0076, 0.01) | 0.0035 (0.003, 0.004) |
| Hepatocellular | 1.75 × 10−2 | 1.0937 (1.0063, 1.1888) | 0.0857 (0.0062, 0.1588) | 0.0081 (0.0003, 0.0159) |
| Penis | 7.09 × 10−13 | 0.9807 (0.9754, 0.986) | −0.0197 (−0.0252, −0.0142) | −0.0068 (−0.0087, −0.0049) |
| Melanoma | 0.0000 | 0.9646 (0.9632, 0.966) | −0.0367 (−0.0382, −0.0352) | −0.0139 (−0.0144, −0.0133) |
| Gallbladder and Biliary | 1.33 × 10−284 | 0.939 (0.9358, 0.9422) | −0.065 (−0.0686, −0.0613) | −0.0216 (−0.0227, −0.0204) |
| Leukaemia—Lymphoid | 4.55 × 10−161 | 0.9207 (0.9152, 0.9262) | −0.0861 (−0.0927, −0.0796) | −0.045 (−0.0482, −0.0417) |
| Hodgkin’s | 0.0000 | 0.9043 (0.9017, 0.9069) | −0.1059 (−0.109, −0.1027) | −0.0383 (−0.0393, −0.0372) |
| Anus | 0.0000 | 0.8729 (0.8682, 0.8776) | −0.1456 (−0.1518, −0.1395) | −0.0522 (−0.0542, −0.0501) |
| Thyroid | 0.0000 | 0.8523 (0.8508, 0.8538) | −0.1733 (−0.1754, −0.1712) | −0.0617 (−0.0624, −0.061) |
| Myeloma | 0.0000 | 0.8404 (0.8381, 0.8427) | −0.1899 (−0.1931, −0.1867) | −0.0669 (−0.0679, −0.0659) |
| Testis | 0.0000 | 0.8054 (0.8038, 0.807) | −0.2416 (−0.2441, −0.2392) | −0.0796 (−0.0803, −0.0789) |
| Non-Hodgkin’s Lymphoma | 0.0000 | 0.8028 (0.8015, 0.8041) | −0.2456 (−0.2477, −0.2436) | −0.0724 (−0.0729, −0.0719) |
| Vulva and Vagina | 0.0000 | 0.7813 (0.7773, 0.7853) | −0.28 (−0.2866, −0.2734) | −0.084 (−0.0857, −0.0823) |
| Vagina | 1.84 × 10−85 | 0.7031 (0.6786, 0.7285) | −0.4223 (−0.4737, −0.3727) | −0.065 (−0.0708, −0.0592) |
| Leukaemia—Myeloid | 0.0000 | 0.6386 (0.6329, 0.6443) | −0.566 (−0.5801, −0.5521) | −0.2466 (−0.2514, −0.2417) |
| Vulva | 0.0000 | 0.591 (0.5808, 0.6015) | −0.6919 (−0.7217, −0.6626) | −0.0926 (−0.0951, −0.09) |
Table key: R.R.—Relative risk; AFE—attributable fraction in the exposed; PAR—population-attributable risk; C.I.—confidence interval; p-value—significance level.